0
0

Chapter 16. Stimulants and Related Drugs

Thomas R. Kosten, M.D.; Mehmet Sofuoglu, M.D., Ph.D.; Michael F. Weaver, M.D.; Sidney H. Schnoll, M.D., Ph.D.; Lori A. Pbert, Ph.D.; Judith K. Ockene, Ph.D., M.Ed.

Sections

Excerpt

Cocaine and amphetamine are psychoactive agents that increase central nervous system (CNS) activity and produce powerful reinforcing effects (e.g., euphoria, elevated mood, high) that contribute to their high abuse liability. Although a great deal has been learned about the reward mechanisms underlying stimulant abuse, the development of effective pharmacotherapy has lagged behind. The pharmacological and behavioral treatment approaches used for cocaine abuse also appear to be applicable to the treatment of amphetamine use, but no treatment agents are U.S. Food and Drug Administration (FDA) approved for this use.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Figure 16C–1. Model for nicotine dependence assessment and treatment.Source. Adapted from Fiore MC, Bailey WC, Cohen SJ, et al. "Treating Tobacco Use and Dependence." Clinical Practice Guideline. Rockville, MD, U.S. Department of Public Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality, June 2000. This document is in the public domain and may be used and reprinted without special permission.
Table Reference Number
Table 16A–1. Pharmacological targets for cocaine dependence
Table Reference Number
Table 16B–1. Stages of phencyclidine intoxication
Table Reference Number
Table 16C–1. Strategies for assisting smokers who are ready to quit
Table Reference Number
Figure 16C–2. Fagerstrom Test for Nicotine Dependence.
Table Reference Number
Table 16C–2. First-line medications for treating nicotine dependence 
Table Reference Number
Table 16C–3. Common elements of practical counseling (problem-solving skills training)
Table Reference Number
Table 16C–4. Potential responses to patient-reported problems that threaten abstinence during prescriptive relapse prevention

References

Carroll KM: Relapse prevention as a psychosocial treatment approach: a review of controlled clinical trials. Exp Clin Psychopharmacol 4:46–54, 1996
 
Carroll KM, Nich C, Ball SA, et al: Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93:713–727, 1998
[PubMed]
 
Cornish JW, Maany I, Fudala PJ, et al: Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend 38:221–227, 1995
[PubMed]
 
Crits-Christoph P, Siqueland L, Blaine J, et al: Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 56:493–502, 1999
[PubMed]
 
George TP, Chawarski MC, Pakes J, et al: Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 47:1080–1086, 2000
[PubMed]
 
Grabowski J, Rhoades H, Elk R, et al: Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 15:163–174, 1995
[PubMed]
 
Grabowski J, Roache JD, Schmitz JM, et al: Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 17:485–488, 1997
[PubMed]
 
Grabowski J, Rhoades H, Schmitz J, et al: Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21:522–526, 2001
[PubMed]
 
Higgins ST, Budney AJ, Bickel WK, et al: Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 51:568–576, 1994
[PubMed]
 
Higgins ST, Wong CJ, Badger GJ, et al: Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol 68:64–72, 2000
[PubMed]
 
Kosten TR, Kleber HD, Morgan C: Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 26:637–639, 1989
[PubMed]
 
Kosten TR, Schottenfeld RS, Ziedonis D, et al: Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 181:358–364, 1993
[PubMed]
 
Kosten TR, George TP, Kosten TA: The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 11:491–499, 2002a
 
Kosten TR, Rosen M, Bond J, et al: Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20:1196–1204, 2002b
 
Kranzler HR, Bauer LO, Hersh D, et al: Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend 38:203–211, 1995
[PubMed]
 
Lima MS, Reisser AA, Soares BG, et al: Antidepressants for cocaine dependence. Cochrane Database Syst Rev (4):CD002950, 2001
 
Ling W, Shoptaw S, Majewska D: Baclofen as a cocaine anti-craving medication: a preliminary clinical study (letter). Neuropsychopharmacology 18:403–404, 1998
[PubMed]
 
Malcolm R, Kajdasz DK, Herron J, et al: A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend 60:161–168, 2000
[PubMed]
 
Margolin A, Kosten TR, Avants SK, et al: A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 40:125–131, 1995
[PubMed]
 
Montoya ID, Levin FR, Fudala PJ, et al: Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend 38:213–219, 1995
[PubMed]
 
Nunes EV, Quitkin FM, Brady R, et al: Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry 148:667–669, 1991
[PubMed]
 
Oliveto AH, Feingold A, Schottenfeld R, et al: Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry 56:812–820, 1999
[PubMed]
 
Schottenfeld RS, Pakes JR, Oliveto A, et al: Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 54:713–720, 1997
[PubMed]
 
Silverman K, Higgins ST, Brooner RK, et al: Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 53:409–415, 1996
[PubMed]
 
Alldredge BK, Lowenstein DH, Simon RP: Seizures associated with recreational drug abuse. Neurology 39:1037–1039, 1989
[PubMed]
 
Anis NA, Berry SC, Burton N, et al: The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-d-aspartate. Br J Pharmacol 79:565–575, 1983
[PubMed]
 
Aronow R, Miceli JN, Done AK: A therapeutic approach to the acutely overdosed PCP patient. Journal of Psychedelic Drugs 12:259–267, 1980
[PubMed]
 
Baldridge EB, Bessen HA: Phencyclidine. Emerg Med Clin North Am 8:541–550, 1990
[PubMed]
 
Balster RH, Woolverton WH: Tolerance and dependence to phencyclidine, in Phencyclidine (PCP): Historical and Current Perspectives. Edited by Domino EF. Ann Arbor, MI, NPP Books, 1981, pp 293–306
 
Bolter A: Issues for inpatient treatment of chronic PCP abuse. Journal of Psychedelic Drugs 12:287–288, 1980
[PubMed]
 
Bowyer JF, Spuhler KP, Weiner N: Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes. J Pharmacol Exp Ther 229:671–680, 1984
[PubMed]
 
Burns RS, Lerner SE: Perspectives: acute phencyclidine intoxication. Clin Toxicol 9:477–501, 1976
[PubMed]
 
Caracci G, Migoni P, Mukherjee S: Phencyclidine abuse and depression. Psychosomatics 24:932–933, 1983
[PubMed]
 
Carroll ME: PCP, the dangerous angel, in The Encyclopedia of Psychoactive Drugs. Edited by Snyder SH. New York, Chelsea House, 1985
 
Chen G, Ensor CR, Russell D, Bohner B: The pharmacology of 1-(1-phenylcyclohexyl) piperidine HCl. J Pharmacol Exp Ther 127:241–250, 1959
[PubMed]
 
De Angelis GG, Goldstein E: Treatment of adolescent phencyclidine (PCP) abusers. Am J Drug Alcohol Abuse 5:399–414, 1978
 
Delgarno PJ, Shewan D: Illicit use of ketamine in Scotland. J Psychoactive Drugs 28:191–199, 1996
 
Giannini AJ, Loiselle RH, Giannini MC, et al: Phencyclidine and the dissociatives. Psychiatr Med 3:197–217, 1984
 
Gorelick DA, Wilkins JN: Inpatient treatment of PCP abusers and users. Am J Drug Alcohol Abuse 15:1–12, 1989
[PubMed]
 
Gorelick DA, Wilkins JN, Wong C: Diagnosis and treatment of chronic phencyclidine (PCP) abuse, in Phencyclidine: An Update. NIDA Research Monograph 64 (DHHS Publ No [ADM] 87-1443). Edited by Clouet DH. Rockville, MD, National Institute on Drug Abuse, 1987, pp 218–228
 
Gorelick PB: Stroke from alcohol and drug abuse: a current social peril. Postgrad Med 88:171–174, 177–178, 1990
 
Green SM, Johnson SE: Ketamine sedation for pediatric procedures, part 2: review and implications. Ann Emerg Med 19:1033–1046, 1990
[PubMed]
 
Grover D, Yeragani VK, Keshanan MS: Improvement of phencyclidine-associated psychosis with ECT. J Clin Psychiatry 47:477–478, 1986
[PubMed]
 
Hansen G, Jensen SB, Chandresh L, et al: The psychotropic effect of ketamine. J Psychoactive Drugs 20:419–425, 1988
[PubMed]
 
Harari MD, Netzer D: Genital examination under ketamine sedation in cases of suspected sexual abuse. Arch Dis Child 70:197–199, 1994
[PubMed]
 
Hurlbut KM: Drug-induced psychoses. Emerg Med Clin North Am 9:31–52, 1991
[PubMed]
 
Hurt PH, Ritchie EC: A case of ketamine dependence (letter). Am J Psychiatry 151:779, 1994
[PubMed]
 
Jansen KLR: Ketamine—can chronic use impair memory? International Journal of the Addictions 25:133–139, 1990
[PubMed]
 
Jansen KLR: Non-medical use of ketamine (letter). BMJ 306:601–602, 1993
[PubMed]
 
Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308, 1991
[PubMed]
 
Johnson KM, Jones SM: Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707–750, 1990
[PubMed]
 
Lahmeyer HW, Stock PG: Phencyclidine intoxication, physical restraints, and acute renal failure: case report. J Clin Psychiatry 44:184–185, 1983
[PubMed]
 
Meng Y, Lichtman AH, Bridgen DT, Martin BR: Pharmacological potency and biodisposition of phencyclidine via inhalation exposure in mice. Drug Alcohol Depend 43:13–22, 1996
[PubMed]
 
Misra AL, Pontani RB, Bartolomeo J: Persistence of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioral effects. Res Commun Chem Pathol Pharmacol 24:431–445, 1979
[PubMed]
 
National Institute on Drug Abuse: Diagnosis and Treatment of Phencyclidine (PCP) Toxicity. Rockville, MD, National Institute on Drug Abuse, 1979
 
Olney JW, Labruyere J, Wang G, et al: NMDA antagonist neurotoxicity: mechanism and prevention. Science 254:1515–1518, 1991
[PubMed]
 
Pearlson GD: Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 148:25–33, 1981
[PubMed]
 
Rappolt RT Sr, Gay GR, Farris RD: Phencyclidine (PCP) intoxication: diagnosis in stages and algorithms of treatment. Clin Toxicol 16:509–529, 1980
[PubMed]
 
Rosen AM, Mukherjee S, Shinbach K: The efficacy of ECT in phencyclidine-induced psychosis. J Clin Psychiatry 45:220–222, 1984
[PubMed]
 
Schuckit MA: Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment, 2nd Edition. New York, Plenum, 1984, pp 152–160
 
Slawson MH, Wilkins DG, Foltz RL, et al: Quantitative determination of phencyclidine in pigmented and nonpigmented hair by ion-trap mass spectrometry. J Anal Toxicol 20:350–354, 1996
[PubMed]
 
Sloan MA, Kittner SJ, Rigamonti D, et al: Occurrence of stroke associated with use/abuse of drugs. Neurology 41:1358–1364, 1991
[PubMed]
 
Smith DE, Wesson DR: Barbiturate and other sedative hypnotics, in Treatment Aspects of Drug Dependence. New York, CRC Press, 1978, pp 117–130
 
Smith RC, Meltzer HY, Arora RC, Davis JM: Effect of phencyclidine on 3H-catecholamine and 3H-serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435–1439, 1977
[PubMed]
 
Soyka M, Krupinski G, Volki G: Phenomenology of ketamine-induced psychosis. Sucht 5:327–331, 1993
 
Tabor BL, Smith-Wallace T, Yonekura ML: Perinatal outcome associated with PCP versus cocaine use. Am J Drug Alcohol Abuse 16:337–348, 1990
[PubMed]
 
Tennant FS, Rawson RA, McCann M: Withdrawal from chronic phencyclidine (PCP) dependence with desipramine. Am J Psychiatry 138:845–847, 1981
[PubMed]
 
Thombs DL: A review of PCP abuse trends and perceptions. Public Health Reports, University of Maryland 104:325–328, 1989
[PubMed]
 
Weaver MF, Jarvis MAE, Schnoll SH: Role of the primary care physician in problems of substance abuse. Arch Intern Med 159:913–924, 1999
[PubMed]
 
Weinstein H, Maayuni S, Glick S, et al: Integrated studies on the biochemical, behavioral and molecular pharmacology of phencyclidine: a progress report, in Phencyclidine (PCP): Historical and Current Perspectives. Edited by Domino EF. Ann Arbor, MI, NPP Books, 1981, pp 131–175
 
White PF, Way WL, Trevor AJ: Ketamine, its pharmacology and therapeutic uses. Anaesthesia 56:119–136, 1982
[PubMed]
 
Wong LK, Biemann K: Metabolites of phencyclidine. Clin Toxicol 9:583–591, 1976
[PubMed]
 
Woolf DS, Vourakis C, Bennett G: Guidelines for management of acute phencyclidine intoxication. Critical Care Update 7:16–24, 1980
[PubMed]
 
Wu JC, Buchsbaum MS, Bunney WE: Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Yakubutsu Seishin Kodo 11:47–48, 1991
[PubMed]
 
Ascher J, Cole J, Colin J-N, et al: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395–401, 1995
[PubMed]
 
Bandura A: Principles of Behavior Modification. New York, Holt, Rinehart, & Winston, 1969
 
Bandura A: Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 84:191–215, 1977
[PubMed]
 
Bock B, Marcus B, King T, et al: Exercise effects on withdrawal and mood among women attempting smoking cessation. Addict Behav 24:399–410, 1999
[PubMed]
 
DiClemente C, Prochaska J, Fairhurst S, et al: The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 59:295–304, 1991
[PubMed]
 
Fiore M, Smith S, Jorenby D, et al: The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 271:1940–1947, 1994
[PubMed]
 
Fiore M, Bailey W, Cohen S, et al: Smoking Cessation: Clinical Practice Guideline No. 18. Rockville, MD, U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996
 
Fiore MC, Bailey WC, Cohen SJ, et al: Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD, U.S. Department of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality, 2000
 
Foulds J: The neurological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 60:571–576, 2006
[PubMed]
 
Foxx R, Brown R: Nicotine fading and self-monitoring for cigarette abstinence or controlled smoking. J Appl Behav Anal 12:111–125, 1979
[PubMed]
 
Froom P, Melamed S, Benbasal J: Smoking cessation and weight gain. J Fam Pract 46:460–464, 1998
[PubMed]
 
Goldfried M, Davison G: Clinical Behavior Therapy. New York, Holt, Rinehart, & Winston, 1976
 
Gourlay S, Benowitz N: Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 62:453–463, 1997
[PubMed]
 
Grunberg N: The effects of nicotine and cigarette smoking on food consumption and taste preferences. Addict Behav 7:317–331, 1982
[PubMed]
 
Heatherton T, Kozlowski L, Frecker R, et al: The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119–1127, 1991
[PubMed]
 
Hofstetter A, Schutz Y, Jequier E, et al: Increased 24-hours energy expenditure in cigarette smokers. N Engl J Med 314:79–82, 1986
[PubMed]
 
Hughes J: Combined psychological and nicotine gum treatment for smoking: a critical review. J Subst Abuse 3:337–350, 1991
[PubMed]
 
Hughes J: Treatment of nicotine dependence: is more better? JAMA 274:171–181, 1995
 
Hughes J: Dependence on and abuse of nicotine replacement: an update, in Nicotine Safety and Toxicity. Edited by Benowitz N. New York, Oxford University Press, 1998, pp 147–160
 
Hughes J, Hatsukami D: The nicotine withdrawal syndrome: a brief review and update. International Journal of Smoking Cessation 1:21–26, 1992
 
Hughes J, Fiester S, Goldstein M, et al: American Psychiatric Association Practice Guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 153:S1–S31, 1996
 
Hughes J, Goldstein M, Hurt R, et al: Recent advances in the pharmacotherapy of smoking. JAMA 281:72–76, 1999
[PubMed]
 
Irvin J, Bowers C, Dunn M, et al: Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol 67:563–570, 1999
[PubMed]
 
Killen J, Fortmann S, Newman B, et al: Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 58:85–92, 1990
[PubMed]
 
Klesges R, Meyers A, Klesges L, et al: Smoking, body weight and their effects on smoking behavior: a comprehensive review of the literature. Psychol Bull 106:204–230, 1989
[PubMed]
 
Law M, Tang J: An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 155:1933–1941, 1995
[PubMed]
 
Lichtenstein E, Brown A: Current trends in the modification of cigarette dependence, in International Handbook of Behavior Modification and Therapy. Edited by Bellack A, Hersen M, Kazdin A. New York, Plenum, 1985, pp 575–612
 
Marlatt G, Gordon J: Determinants of relapse: implications for the maintenance of behavior change, in Behavioral Medicine: Changing Health Lifestyles. Edited by Davidson P, Davidson S. New York, Brunner/Mazel, 1980, pp 410–452
 
Massachusetts Department of Public Health: 1997 Cigarette Nicotine Disclosure Report as Required by Massachusetts General Laws. Chapter 307B, Report No CMR660.000, January 16, 1998
 
Ockene JK, Adams A, Pbert L, et al: The physician-delivered smoking intervention project (PDSIP): factors that determine how much the physician intervenes with smokers. J Gen Intern Med 9(7):379–384, 1994
[PubMed]
 
Ockene J, Emmons K, Mermelstein R, et al: Relapse and maintenance issues for smoking cessation. Health Psychol 19:17–31, 2000
[PubMed]
 
Perkins K: Metabolic effects of cigarette smoking. J Appl Physiol 72:401–409, 1992
[PubMed]
 
Schuh K, Schuh L, Henningfield J, et al: Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 130:352–361, 1997
[PubMed]
 
Schwartz J: Methods of smoking cessation. Med Clin North Am 76:451–476, 1992
[PubMed]
 
Shiffman S: Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162:1267–1276, 2002
[PubMed]
 
Sutherland G, Stapleton J, Russell M, et al: Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324–329, 1992
[PubMed]
 
U.S. Department of Health and Human Services: The Health Benefits of Smoking Cessation: A Report of the Surgeon General (DHHS Publ No CDC 90-8416). Atlanta, GA, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990, pp 580–616
 
Velicer W, Fava J, Prochaska J, et al: Distribution of smokers by stage in three representative samples. Prev Med 48:401–411, 1995
 
Wack J, Rodin L: Smoking and its effects on body weight and the systems of caloric regulation. Am J Clin Nutr 35:366–380, 1982
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 8.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 4.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation